EUCOPE News by Tag — Rare Disease

Filtered by Tag: Rare Disease

Partnerships - March 25, 2021


Working group of European rare disease experts developed  nine principles to foster greater consistency in Value Assessment and Funding Process in rare diseases. The group explored the pricing and reimbursement systems for OMPs in selected European countries to analyse where they align with or diverge from… read more

Partnerships - March 25, 2021


Multi-stakeholder initiative commissioned by the Belgian National Institute of Health and Disability Insurance (INAMI-RIZIV) aimed at fostering stakeholders’ agreement of what real-world data (RWD) can be collected for highly innovative technologies, to generate real-world evidence (RWE) that informs decisions by healthcare systems, clinicians and patients…. read more

Partnerships - March 25, 2021

European Expert Group on OD Incentives

Multidisciplinary expert group including researchers, academia, patient representatives, investors and industry Input to strengthen the OMP Incentives Environment in Europe focusing on addressing unmet needs and supporting delivery of continued innovation where treatments exist; finding ways to optimise and accelerate OD regulatory pathways and identifying… read more

EUCOPE Resources / Press Releases - January 7, 2021

EUCOPE’s response to the Orphan Medicinal Products and Paediatrics Inception Impact Assessment

EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies submitted its response to the Paediatric and Orphan Medicinal Products (OMPs) inception impact assessment. EUCOPE represents 130 companies, many focused on rare diseases, largely small to medium-sized, playing a key role… read more

News - December 17, 2020

EMA & HMA Joint Strategy 2021-2025

Published on 8 December, the European Medicines Agency (EMA) and Heads of Medicines Agency (HMA) Joint Strategy looks into six strategic focus areas: (1) Availability and accessibility of medicines, (2) Digital tools and digital transformation, (3) Innovation, (4) Antimicrobial resistance, (5) Supply chain challenges, and… read more